The Alzheimer’s Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) jointly announce that the Accelerating Drug Discovery for Frontotemporal Degeneration RFP is now accepting letters of intent.
This RFP supports innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug development programs for frontotemporal dementia (FTD). The average duration of the award is one year with potential for follow-on funding, and the average award amount is $100,000-$150,000 based on stage and scope of research.
For scientific inquiries, contact mowen@alzdiscovery.org.
Eligibility
Funding is open to researchers and clinicians in the U.S. and worldwide working in:
- Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
- Biotechnology companies that demonstrate a clear need for nonprofit funding. Existing companies and new spinouts are both eligible.
Because of our Venture Philanthropy model, all funding provided by the ADDF is through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Return on investment can include equity, convertible notes or royalties and are determined on a case-by-case basis.
Please review our Funding Policies before applying.
Application
Review the Application Instructions* for steps on applying.
The ADDF considers its application process an iterative one and would be happy to talk to you about your program.
*Please note that you will be following the same application instructions as the Core RFPs.
For more information click here